The company aims to improve existing immunoassays by providing additional sensitivity to currently available antibody-based test, as well as allowing researchers to monitor new markers that are not readily detectable with current technology. This may lead to earlier and more accurate diagnosis of diseases such as cancer, cardiovascular disorders, and Alzheimer’s disease. Better diagnosis results in simpler treatments with more positive outcomes for patients and less costs.
The company said that the system extends the sensitivity over current detection technologies while being easily incorporated into assays that use a peroxidase-based detection system.
Judith Luborsky, professor and associate dean for research at College of Health Sciences, and director of laboratory for Ovarian Cancer Research, said: “We find the resolution at low concentrations to be an exciting benefit in our ovarian cancer and infertility research. The technology was easily integrated into existing tests with minimal optimization and provided excellent improvements. In fact, we have included Sword technology in several grants we are currently applying for.”
Dave Dingott, founder and CEO of Sword Diagnostics, said: “We are pleased with the positive reception our technology has received from the market. The key opinion leaders have found it particularly useful for highly sensitive ELISAs. The Raman plate reader allows current ELISA users to continue using their 96-well format, making conversion to our technology extremely simple and cost effective.”
